Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Equity Average (2016 - 2025)

Cytosorbents (CTSO) has disclosed Equity Average for 13 consecutive years, with $10.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 33.12% year-over-year to $10.3 million, compared with a TTM value of $10.3 million through Sep 2025, down 33.12%, and an annual FY2024 reading of $17.3 million, down 41.23% over the prior year.
  • Equity Average was $10.3 million for Q3 2025 at Cytosorbents, down from $13.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $78.2 million in Q1 2021 and bottomed at $10.3 million in Q3 2025.
  • Average Equity Average over 5 years is $36.3 million, with a median of $26.7 million recorded in 2023.
  • The sharpest move saw Equity Average soared 532.69% in 2021, then tumbled 50.09% in 2023.
  • Year by year, Equity Average stood at $66.6 million in 2021, then tumbled by 44.05% to $37.3 million in 2022, then plummeted by 43.25% to $21.1 million in 2023, then plummeted by 42.09% to $12.2 million in 2024, then fell by 15.86% to $10.3 million in 2025.
  • Business Quant data shows Equity Average for CTSO at $10.3 million in Q3 2025, $13.1 million in Q2 2025, and $12.8 million in Q1 2025.